Company intelligence / Profile preview

Life Science Capital Master Fund

George Town, Cayman Islands

Ownership: Private
Development stage: Other

Overview

Life Science Capital Master Fund was a specialized investment fund focused on the biotechnology and life sciences sectors. Managed by Life Science Capital LLP, the fund was active in the mid-2000s, providing venture capital and growth equity to clinical-stage biopharmaceutical companies. Its portfolio included notable investments in companies such as Acorda Therapeutics and Nile Therapeutics. The fund was led by Thomas O. Daniel, a veteran biotech executive who later held senior leadership roles at Celgene and Arch Venture Partners.

Industry: Investors

Beyond the preview

Go deeper on Life Science Capital Master Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Life Science Capital Master Fund.

Explore the full profile